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Abstract
Background: We sought to assess vulvodynia incidence and risk factors among those with and without pre-
morbid urogenital symptoms.
Methods: Women’s Health Registry members who completed a baseline assessment in 2004 were sent a 2-year
and 4-year follow-up survey containing a validated screen for vulvodynia. Subgroup analysis of vulvodynia
incidence rates was performed, and risk factors associated with incidence were assessed.
Results: Of 1037 original enrollees, 723 (69.7%) completed consecutive surveys (initial and 2-year or initial, 2-
year, and 4-year), 660 of whom did not have current or past vulvodynia at baseline. Of these 660, 71 (10.8%) first
met criteria for vulvodynia within the 4-year period, for an annual incidence rate of 3.1% (95% confidence
interval [CI] 2.5-4.0). Baseline strict controls were less likely to develop criteria for vulvodynia diagnosis (annual
incidence rate of 1.4%) compared to those with an intermediate phenotype (presence of dyspareunia or history of
short-term vulvar pain), for whom the incidence rate was 5.6% ( p < 0.001). Risk factors for incident vulvodynia
differed between these two groups. Among the strict controls, an increased risk was noted among younger
women (incidence rate ratio) [IRR] 3.6). For those with an intermediate phenotype, risk was increased among
nonwhite women and those reporting pain with or after intercourse (IRR 2.2, 3.4, and 3.1, respectively). In both
control groups, incident vulvodynia risk increased among those reporting urinary burning at enrollment (IRR
4.2 and 2.8 for strict and intermediate phenotype controls, respectively).
Conclusions: The annual incidence of vulvodynia is substantial (3.1%) and is greater among women reporting a
history of dyspareunia or vulvar pain that did not meet criteria for vulvodynia compared to those without this
history, suggesting that generalized urogenital sensitivity may be a common underlying mechanism predating
the clinical presentation of vulvodynia.
Introduction
Vulvodynia is a disorder characterized by hypersensi-tivity at the vulva or vaginal introitus (vestibule) that
typically causes sexual intercourse to be painful or intolera-
ble.1 Its prevalence has been reported to be between 3.1% and
15%.2–5 Limited data are available on the incidence of vul-
vodynia in the general population6,7 and on the relationship
between prior experiences with vulvar symptoms and onset
of vulvodynia.
Cross-sectional studies have suggested that vulvodynia is
associated with other pain symptoms and with comorbid
medical conditions, such as fibromyalgia, chronic fatigue
syndrome, recurrent vulvovaginal infections, and yeast in-
fections.1,6,8–11 However, the cross-sectional study design
does not allow differentiation between those symptoms that
are precursors to vs. comorbid with vulvodynia. Few pro-
spective data are available.6,7 A prior analysis from this cur-
rent prospective study after 2 years of follow-up estimated the
annual incidence of vulvodynia to be 1.8% among strict con-
trols (defined as those without dyspareunia or a history of
vulvar pain)6 and found younger age and a history of pain
after intercourse to be associated with the new onset of vul-
vodynia.6 After 4 years of follow-up, the current analysis re-
assessed vulvodynia incidence rates among women who did
not meet criteria for current or past vulvodynia at enrollment
but who might not have been totally asymptomatic (a defi-
nition of greater relevance to the general population) and
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evaluated the relationship between the presence of premorbid
urogenital symptoms and the onset of vulvodynia during the
study period.
Institutional review board approval for this study was
obtained from the University of Michigan Medical Human
Subjects Committee.
Materials and Methods
In 2004, 1037 members of the University of Michigan’s
Women’s Health Registry completed either an online or a
written survey regarding the presence of symptoms sugges-
tive of vulvodynia.12 Further clinical investigation of a subset
of those women demonstrated excellent reliability and va-
lidity of survey responses for predicting vulvodynia,12 and no
further validation was performed in this study. In 2006 and
2008, follow-up surveys were sent to all women who had
participated in the baseline assessment. Women with e-mail
addresses were sent links to an online survey (Survey-
Monkey.com, Portland, OR), and a written survey was mailed
to all women who had no valid e-mail address and to those
from whom no completed online surveys were received. A
total of 723 (69.7%) women completed the 2-year survey,6 660
(63.6%) completed the 4-year follow-up survey, and 573
(55.3%) completed all three surveys.
Participants were assigned to one of four clinical statuses,
based on previously validated survey responses.12 Cases were
defined as women having current vulvar pain (at the vaginal
opening) that occurred over ‡ 3 months. Past cases were defined
as women who reported previous symptoms of vulvodynia but
did not have them at present. Strict control status was assigned
based on reporting no current pain with intercourse and no
history of vulvar pain lasting ‡ 3 months. The intermediate
phenotype control category was composed of two subgroups:
those women who reported pain with intercourse within the
past 6 months but no vulvar pain and those who reported
having had vulvar pain at some point but did not meet criteria
for current or past vulvodynia (typically denying pain occurred
for ‡ 3 months). Those with data at consecutive rounds (initial
and 2-year but no 4-year follow-up or initial, 2-year, and 4-year
follow-up rounds) were included in the analysis (n = 723, or
69.7% of the initial cohort). Of these, 660 (91.3%) did not screen
positive for vulvodynia at the initial round and could be eval-
uated for new onset vulvodynia over the course of the study.
Descriptive statistics were calculated for all variables.
Characteristics (at enrollment) of the 660 women who com-
pleted consecutive surveys, compared to those who also did
not screen positive for vulvodynia at the baseline but who did
not complete consecutive surveys (n = 267), were assessed
using chi-square analysis. The annual incidence rate and risk
factors for vulvodynia overall and for various diagnostic
subgroups were estimated using a negative binomial regres-
sion model (generalized linear model), with demographic and
premorbid conditions included as independent variables, the
logarithm of time (minimum of incidence-free observation
time or time until incidence) used as the offset, and the annual
incidence rate as the outcome.
Results
Characteristics of the potential participants for this analy-
sis, stratified by whether they completed consecutive surveys,
were compared (Table 1). This consisted of the 660 women
included in the analysis who filled out consecutive surveys
(including the initial and 2-year only [n = 165] or the initial,
2-year, and 4-year surveys [n = 495]) and those who did not
(n = 267) (Table 1). Compared to those lost to follow-up, those
with consecutive data were more likely to be older and non-
white and to report higher education and household income.
They were also slightly more likely to have an intermediate
symptom phenotype, compared to being a strict control, than
were those who did not complete consecutive surveys.
Prevalence of vulvodynia
The proportion of participants completing consecutive
surveys who met criteria for vulvodynia at the 2-year and the
4-year follow-up were 9.4% and 10.8%, respectively. How-
ever, the specific individuals constituting the case or noncase
subgroups differed between rounds. For example, of the 573
women completing both the 2-year and the 4-year follow-up
rounds, 25 (44.6%) of the 56 cases at the 2-year round were still
cases at the 4-year follow-up, with the rest no longer reporting
ongoing symptoms.
Incidence of vulvodynia
The incidence rates of vulvodynia, categorized by enroll-
ment case-control classification, are shown in Table 2. Over
the 4-year follow-up period, of 660 participants who did not
report current or past vulvodynia at the initial survey (rang-
ing in age from 19 to 83 years), a total of 71 (10.8%) developed
symptoms of vulvodynia, for an estimated annual incidence
rate of 3.1% (95% confidence interval [CI] 2.5, 4.0). The annual
incidence rate of vulvodynia among those defined as strict
controls at enrollment was 1.4%, similar to that reported
previously using a similar definition of ‘‘strict control.’’6 We
further evaluated the incidence rates over the 4-year period
among each of the diagnostic groups, including those with
Table 1. Characteristics of Those Who Were Not
a Case or Past Case at Enrollment (n = 927)
and Who Did (Included in Subsequent Analyses)





(n = 660) %
No consecutive
surveys
(n = 267) %
p
valueb
Age ‡ 50 years 42.6 33.2 0.009
Married 59.8 54.4 0.130
White 88.0 80.7 0.004









Pain with first tampon 30.5 36.8 0.081
Case-control status at enrollment




aVariables based on enrollment data.
bBased on chi-square analysis.
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intermediate symptoms at enrollment who did not meet cri-
teria for vulvodynia (Table 2). The annual incidence rate
among those with an intermediate phenotype at enrollment
was substantially higher (annual incidence of 5.6%) than that
for the strict control group (annual incidence of 1.4/100
women), as shown ( p < 0.001).
Risk factors for incident vulvodynia
Table 3 compares the baseline characteristics of those who
became incident vulvodynia cases by the time of the 4-year
follow-up in contrast to those who remained noncases, for all
controls, and also stratified by whether they were strict con-
trols or had an intermediate phenotype at the time of the
initial survey. Shown are the results for the multivariable
analyses, controlling for age, ethnicity, and income. Among
the women in general, new onset vulvodynia was associated
with a number of premorbid characteristics at baseline (in-
cluding younger age [ < 50], history of a yeast infection in the
previous 2 years, pain reported with first tampon use or first
intercourse, a history of pain with intercourse or pain after
intercourse), with vulvar or urinary burning, with having an
intermediate phenotype (as compared to being a strict con-
trol), and with a trend noted with genital itching. Among
strict controls at enrollment, new onset vulvodynia was less
likely in older women ( ‡ 50 years) and more likely in those
reporting urinary burning at enrollment. Among those with
an intermediate phenotype, incident vulvodynia cases were
more likely to occur among nonwhite women and among
those reporting pain after intercourse or urinary burning or
both on their enrollment survey.
Discussion
The incidence of vulvodynia, as diagnosed using validated
survey-based criteria,12 is substantial, and occurs over a wide
range of ages (23–78 years). However, this incidence rate
varies considerably among women who fall into different
noncase subgroups. Those categorized as strict controls at
enrollment (no dyspareunia or past vulvar pain lasting > 3
months) were less likely to develop vulvodynia (incidence
rate 1.4%) compared to those reporting dyspareunia without
ongoing vulvar pain or those with a history of vulvar pain not
meeting criteria for current or past vulvodynia (incidence rate
5.6%). Given this increased risk, healthcare providers may
wish to educate women with these symptoms about the
characteristics of vulvodynia, thereby increasing the possi-
bility of earlier identification and treatment should the
symptoms progress to those consistent with this disorder.
Data on whether oral contraceptive (OC) use is associated
with the presence of vulvodynia are conflicting, with some
reports suggesting an association13–15 and others, including
this study, suggesting none.16,17 Few account for whether the
OCs were started before or after the development of the vul-
var symptoms. We found no association between current use
of OCs as was reported at enrollment with new onset of
vulvodynia over the 4-year follow-up period.
Risk factors identified included not only those previously
suggested, such as pain after intercourse,6 but also a newly
identified risk factor of urogenital symptoms, such as vulvar
burning and urinary burning, reported before the onset of
vulvar pain meeting criteria for vulvodynia. A history of yeast
infections has long been reported to be associated with vul-
vodynia.8,18 History of yeast infections was associated with
risk of new onset vulvodynia only among those in the strict
control group but not when controlled for age, ethnicity, and
income. Because the diagnosis of yeast infections is often
made based on symptoms alone or on in-office microscopic
assessment without culture, the validity of this reported his-
tory remains uncertain19 and needs laboratory confirmation
in a longitudinal study.
A history of pain after intercourse and the reported pres-
ence of genital symptoms, such as burning with urination,
were associated with subsequent onset of vulvodynia among
both strict controls and those with an intermediate phenotype.
The presence of these symptoms before the diagnosis of vul-
vodynia suggests that a premorbid state of neuronal hyper-
sensitivity in the introital area may exist that only later meets
criteria for clinical vulvodynia.
There are limitations to this study. Validation of case status
in the office was conducted previously on a subset of partic-
ipants at the time of the baseline survey,6 but no further in-
office validation was performed for the 2-year and 4-year
follow-up rounds. Based on previous validation studies, the
probability of misclassification among a small proportion of
participants based on concurrent infection or dermatologic
disorders is thought to be small.1,12 In addition, although the
cohort of women assessed in this series of surveys was not
selected from a clinic-based population or from those with
genitourinary symptoms, participation in the Women’s
Health Registry, from which the women in this study were
enrolled, is voluntary and may not represent the population at
large.
Table 2. Annual Incidence Rates of Vulvodynia
Among Those with Noncase Status at Enrollment





per year) (95% CI)a
All control women who were not a case or past
case at enrollment
660 71 3.1 (2.5-4.0)
Control women who had no pain with
intercourse and no history of vulvar pain
372 18 1.4 (0.9-2.2)
Control women with intermediate phenotypesb 288 53 5.6 (4.1-7.5)
aUsing a negative binomial with log link model.
bIntermediate phenotypes include those reporting pain with intercourse but no vulvar pain or a history of vulvar pain not lasting ‡ 3
months.
CI, confidence interval.





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































This 4-year follow-up study of women volunteers in a
Women’s Health Registry indicates that the annual incidence
of vulvodynia over time is approximately 3% and that a new
onset of symptoms of vulvodynia is more likely to develop in
women with intermediate symptoms of dyspareunia or with a
history of short-term vulvar pain than in those denying this
history. Further, women with new onset vulvodynia fre-
quently have a premorbid history of nonspecific urogenital
symptoms that may suggest neuronal hypersensitivity, which
may allow detection of those at increased risk for subsequent
vulvodynia.
Acknowledgments
We thank Sue Countryman for managing this project, Jill
Bowdler for her survey management and secretarial assis-
tance, and the Department of Family Medicine at the Uni-
versity of Michigan for partial funding of this project.
Disclosure Statement
No competing financial interests exist.
References
1. Harlow BL, Vazquez G, MacLehose RF, Erickson DJ, Oakes
JM, Duval SJ. Self-reported vulvar pain characteristics and
their association with clinically confirmed vestibulodynia. J
Womens Health 2009;18:1333–1340.
2. Harlow BL, Wise LA, Stewart EG. Prevalence and predictors
of chronic lower genital tract discomfort. Am J Obstet Gy-
necol 2001;185:545–550.
3. Reed BD, Crawford S, Couper M, Cave C, Haefner HK. Pain
at the vulvar vestibule: A web-based survey. J Lower Genit
Tract Dis 2004;8:48–57.
4. Bachmann G, Rosen R, Arnold L, et al. Chronic vulvar and
other gynecologic pain: Prevalence and characteristics in a
self-reported survey. J Reprod Med 2006;51:3–9.
5. Reed BD, Harlow SD, Sen A, et al. Prevalence and demo-
graphic characteristics of vulvodynia in a population-based
sample. Am J Obstet Gynecol 2012;206:170 e171–179.
6. Reed BD, Haefner HK, Sen A, Gorenflo DW. Vulvodynia
incidence and remission rates among adult women: A 2-year
follow-up study. Obstet Gynecol 2008;112:231–237.
7. Sutton JT, Bachmann GA, Arnold LD, Rhoads GG, Rosen
RC. Assessment of vulvodynia symptoms in a sample of
U.S. women: A follow-up national incidence survey. J Wo-
mens Health 2008;17:1285–1292.
8. Arnold LD, Bachmann GA, Rosen R, Kelly S, Rhoads GG.
Vulvodynia: Characteristics and associations with co-
morbidities and quality of life. Obstet Gynecol 2006;107:
617–624.
9. Arnold LD, Bachmann GA, Rosen R, Rhoads GG. Assess-
ment of vulvodynia symptoms in a sample of U.S. women:
A prevalence survey with a nested case-control study. Am J
Obstet Gynecol 2007;196:128 e121–126.
10. Zolnoun DA, Rohl J, Moore CG, Perinetti-Liebert C, Lamvu
GM, Maixner W. Overlap between orofacial pain and vulvar
vestibulitis syndrome. Clin J Pain 2008;24:187–191.
11. Reed BD, Harlow SD, Legocki LJ, Edwards RM, Sen A,
Haefner HK. Vulvodynia and other chronic pain co-
morbidities. J Low Genit Tract Dis 2011;15:S14.
12. Reed BD, Haefner HK, Harlow SD, Gorenflo DW, Sen A.
Reliability and validity of self-reported symptoms for pre-
dicting vulvodynia. Obstet Gynecol 2006;108:906–913.
13. Bazin S, Bouchard C, Brisson J, Morin C, Meisels A, Fortier
M. Vulvar vestibulitis syndrome: An exploratory case-
control study. Obstet Gynecol 1994;83:47–50.
14. Sjoberg I, Nylander Lundqvist EN. Vulvar vestibulitis in the
north of Sweden. An epidemiologic case-control study.
J Reprod Med 1997;42:166–168.
15. Bouchard C, Brisson J, Fortier M, Morin C, Blanchette C. Use
of oral contraceptive pills and vulvar vestibulitis: A case-
control study. Am J Epidemiol 2002;156:254–261.
16. Harlow BL, Vitonis AF, Stewart EG. Influence of oral con-
traceptive use on the risk of adult-onset vulvodynia. J Re-
prod Med 2008;53:102–110.
17. Foster DC. Case-control study of vulvar vestibulitis syn-
drome. J Womens Health 1995;6:677–680.
18. Edwards L. New concepts in vulvodynia. Am J Obstet Gy-
necol 2003;189:S24–30.
19. Berg AO, Heidrich FE, Fihn SD, et al. Establishing the cause
of genitourinary symptoms in women in a family practice.
Comparison of clinical examination and comprehensive
microbiology. JAMA 1984;251:620–625.
Address correspondence to:
Barbara D. Reed, M.D., MSPH
University of Michigan
Department of Family Medicine
1018 Fuller Street
Ann Arbor, MI 48104-1213
E-mail: barbr@umich.edu
LONGITUDINAL VULVODYNIA STUDY 1143
